TriSalus Life Sciences Reports 53% Revenue Growth in 2025, Reaffirms 2026 Guidance
Event summary
- TriSalus Life Sciences reported $45.2 million in revenue for 2025, a 53% increase year-over-year, driven by TriNav system sales.
- Fourth-quarter 2025 net sales were $13.2 million, a 60% year-over-year increase.
- The company raised $46 million in a public offering to support growth initiatives.
- 2026 revenue guidance reaffirmed at $60 million to $62 million.
- Gross margin improved to 86.7% in Q4 2025, up from 85.3% in Q4 2024.
The big picture
TriSalus Life Sciences is capitalizing on the growing adoption of its TriNav product suite and PEDD platform across solid tumor indications. The company's strategic focus on expanding into new clinical settings and enhancing its embolization toolkit positions it to compete in the evolving interventional radiology market. With $46 million in fresh capital, TriSalus aims to accelerate its commercial and clinical initiatives, potentially broadening its addressable market.
What we're watching
- Commercial Expansion
- Whether TriSalus can sustain its 60% year-over-year sales growth in 2026 through expanded interventional radiology engagement.
- Product Innovation
- The pace at which TriSalus advances new PEDD product launches and their impact on market differentiation.
- Financial Discipline
- How effectively TriSalus manages its $46 million growth capital to achieve profitability on its expected timeline.
Related topics